“…Namely, although international guidelines for flow cytometry diagnosis of hematological diseases recommend the use of a lymphocyte screening tube containing markers for B‐lymphocytes (CD19, CD20, kappa, lambda), T‐lymphocytes (CD3, CD4, CD5, CD8, CD38, TCRγδ) and NK‐lymphocytes (CD56), for reasons directly related to financial costs and time savings, some centers around the world, especially those located in countries of low income, do not start the immunophenotypical study using the lymphocyte screening tube. Rather, they resort to the old fashioned, but yet effective and cheap, combination of an automatic complete blood count plus peripheral blood smear review with the aim to decide the initial antibody panel to be used . In this scenario, based on the well‐known much higher prevalence of mature B‐cell neoplasms (over 90% worldwide) when compared to mature T and NK‐cell neoplasms , the presence of lymphocytosis rationally points to the initial use of a panel with specificity for the diagnosis of a mature B‐cell lineage disease and which, usually, does not include monoclonal antibodies with specificity for the CD8 antigen.…”